ArticlePharmacological reports : PR2026
Phase-specific involvement of BDNF-TrkB signaling in HSV-1-induced herpetic pain and its transition to postherpetic neuralgia-like pain.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPostherpetic neuralgia (PHN) is a chronic neuropathic pain condition that develops following herpes zoster, yet the molecular mechanisms underlying the transition from acute herpetic pain to chronic pain remain unclear. Brain-derived neurotrophic factor (BDNF)-TrkB signaling is implicated in central sensitization, but its role in virus-induced pain chronification is unknown. Therefore, this study investigated the temporal involvement of BDNF-TrkB signaling in acute herpetic pain and in the development of PHN-like pain.
methodsA herpes simplex virus type-1 (HSV-1)-induced mouse model of herpetic pain was used to evaluate temporal changes in neurotrophin and Trk receptor expression in the dorsal root ganglia (DRG) and spinal dorsal horn. Pharmacological interventions included intrathecal administration of anti-BDNF, anti-Trk receptor antibodies or TrkB-Fc chimera, and repeated systemic treatment with the TrkB antagonist ANA-12 during the acute phase. Mechanical allodynia was behaviorally assessed.
resultsBDNF mRNA expression was significantly upregulated in ipsilateral DRG and spinal dorsal horn during the acute phase, whereas neurotrophin-3 remained unchanged and nerve growth factor showed only transient increases in DRG. No neurotrophin or Trk receptor changes were observed in established PHN-like pain. Intrathecal administration of anti-BDNF antibody, anti-TrkB antibody, or TrkB-Fc chimera significantly attenuated acute mechanical allodynia, whereas anti-TrkA and anti-TrkC antibodies showed no significant effects. None of these interventions affected established PHN-like pain. Repeated administration of the TrkB antagonist ANA-12 during the acute phase attenuated acute herpetic pain and significantly reduced the subsequent incidence of PHN-like pain. DISCUSSION: BDNF-TrkB signaling plays a phase-specific role in herpetic pain, driving acute pain expression and the transition to chronic PHN-like pain but not pain maintenance. Early TrkB inhibition may represent a disease-modifying strategy to prevent viral pain chronification.
Indexed as
Identifiers
42455233What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.